Gerald Quartey, an 18-year-old from New Jersey, is the first patient to receive the Lyfgenia gene therapy outside of clinical trials, now FDA-approved for patients aged 12 and older. This innovative treatment involves modifying a patient’s stem cells to produce healthy red blood cells after undergoing chemotherapy. Gerald, who suffered greatly from sickle cell disease, expressed how pain limited his life. His mother, who tragically lost another son to the condition, supports this new hope for treatment. The procedure is also covered by insurance, making it accessible to patients.
"We are essentially curing patients of their disease"
"Most of the time, I would just be inside because I was in pain"
Collection
[
|
...
]